Mettler-Toledo International Inc. MTD SPX
Company Overview
Mettler-Toledo International Inc. manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. It operates through five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other Operations. The company offers laboratory instruments, such as laboratory balances, liquid pipetting solutions, real-time analytics, titrators, pH meters, process analytics sensors and analyzer technologies, density and refractometry instruments, and thermal analysis systems; and other analytical instruments, including UV/VIS spectrophotometers, moisture analyzers, and cell counters, as well as LabX, a laboratory software platform to manage and analyze data generated by its instruments and automate workflows. It also provides industrial instruments comprising industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, metal detectors, x-ray systems, checkweighers, and camera-based imaging equipment. In addition, the company offers retail weighing solutions consisting of weighing and software solutions, AI-driven image recognition solutions for fresh goods, and automated packaging and labeling solutions for the meat backroom. The company serves pharmaceutical and biotech companies, independent research organizations, and testing labs; food manufacturers and retailers; chemical, specialty chemicals, and cosmetics companies; transportation and logistics, metals, and electronics industries; and academic community through its direct sales force and indirect distribution channels. Mettler-Toledo International Inc. was incorporated in 1991 and is headquartered in Greifensee, Switzerland.
Why Investors Should Care
Maintains a net profit margin of 21.4%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $4.03B (+4.0% YoY); net profit $869.19M.
- Trailing 12 Months Year-on-year growth — revenue +7.2%, earnings +6.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 4.3%, profit CAGR 8.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 4.28% |
| 1 Year: | 7.20% |
Compounded Profit Growth
| 5 Years: | 8.94% |
| 1 Year: | 6.70% |
Stock Price Performance
| 1 Year: | +10.13% |
| 6 Months: | -11.47% |
| 3 Months: | -2.31% |
| 1 Month: | +15.21% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)65.65 · Neutral
P/E of 30.91 is above the sector median of 25.41 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 21.4%.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MTD Mettler-Toledo International Inc. SPX | 1,314.83 | 30.91 | $26.57B | 0.00% | - | - | 4.28% | 8.94% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 660.82M | 722.00M | 734.85M | - | 679.45M | 731.37M | 753.87M | - | 649.16M | 690.67M | 807.36M | - | 804.39M | 924.35M | 951.95M | - | 897.79M | 978.39M | 985.85M | - | 928.74M | 982.12M | 942.46M | 925.95M | 946.75M | 954.53M | 883.74M | 983.22M | 1.03B | 947.13M |
| Gross Profit | 339.53M | 390.75M | 299.91M | 347.58M | 369.49M | 418.61M | 343.39M | 375.61M | 400.98M | 455.77M | 374.93M | 412.62M | 419.25M | 477.57M | 388.32M | 419.54M | 435.06M | 498.30M | 374.41M | 397.97M | 469.61M | 559.04M | 471.70M | 536.90M | 555.82M | - | 519.59M | 571.66M | 584.66M | - | 546.57M | 583.54M | 559.54M | 548.13M | 565.67M | 572.47M | 525.88M | 579.88M | 609.46M | 555.82M |
| Net Income | 88.86M | 123.35M | 65.67M | 79.59M | 101.33M | 137.78M | 92.47M | 101.58M | 104.95M | 76.98M | 93.30M | 111.47M | 126.65M | 181.19M | 111.81M | 127.16M | 129.40M | 192.75M | 98.11M | 126.56M | 161.77M | 149.66M | 149.66M | 184.76M | 203.69M | 174.00M | 174.00M | 212.07M | 220.60M | 188.43M | 188.43M | 213.93M | 201.63M | 177.51M | 221.81M | 211.52M | 163.59M | 202.35M | 217.49M | 169.45M |
| Diluted EPS | 3.16 | 4.44 | 2.40 | 2.93 | 3.77 | 5.17 | 3.48 | 3.84 | 3.99 | 2.93 | 3.58 | 4.31 | 4.93 | 7.11 | 4.42 | 5.06 | 5.20 | 7.84 | 4.03 | 5.22 | 6.68 | 9.03 | 6.32 | 7.85 | 8.71 | - | 7.55 | 9.29 | 9.76 | - | 8.47 | 9.69 | 9.21 | 8.24 | 10.37 | 9.96 | 7.81 | 9.76 | 10.57 | 8.33 |
| R&D Expense | 29.71M | - | 28.97M | 30.70M | 30.14M | - | 31.20M | 32.58M | 32.20M | - | 34.71M | 35.31M | 34.84M | - | 36.05M | 36.58M | 36.02M | - | 34.39M | 31.19M | 34.66M | - | 39.27M | 42.60M | 42.28M | - | 43.03M | 44.02M | 44.13M | - | 45.48M | 47.24M | 46.13M | 46.41M | 45.77M | 47.12M | 46.35M | 49.28M | 51.14M | 51.27M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.97B | 1.73B | 1.97B | 2.31B | 2.34B | 2.38B | 2.49B | 2.40B | 2.51B | 2.73B | 2.94B | 3.01B | 3.09B | 3.72B | 3.92B | 3.79B | 3.87B | 4.03B |
| Gross Profit | 993.08M | 889.34M | 1.04B | 1.22B | 1.24B | 1.28B | 1.36B | 1.35B | 1.44B | 1.58B | 1.68B | 1.74B | 1.80B | 2.17B | 2.31B | 2.24B | 2.33B | 2.39B |
| Net Income | 202.78M | 172.59M | 232.15M | 269.49M | 290.85M | 306.09M | 338.24M | 352.82M | 384.37M | 375.97M | 512.61M | 561.11M | 602.74M | 768.99M | 872.50M | 788.78M | 863.14M | 869.19M |
| Diluted EPS | 5.79 | 5.03 | 6.80 | 8.21 | 9.14 | 9.96 | 11.44 | 12.48 | 14.22 | 14.24 | 19.88 | 22.47 | 24.91 | 32.78 | 38.41 | 35.90 | 40.48 | 42.05 |
| R&D Expense | 102.28M | 89.69M | 97.03M | 116.14M | 112.53M | 116.35M | 123.30M | 119.08M | 119.20M | 128.31M | 141.07M | 143.95M | 140.10M | 169.77M | 177.12M | 185.28M | 189.36M | 199.37M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 1.72B | 2.28B | 2.11B | 2.02B | 2.15B | 1.97B | 1.96B | 2.17B | 2.55B | 2.62B | 2.79B | 2.81B | 3.33B | 3.49B | 3.36B | 3.24B | 3.71B |
| Total Equity | 581.29M | 503.25M | 711.14M | 771.58M | 781.14M | 827.22M | 935.05M | 719.60M | 580.46M | 434.94M | 547.28M | 590.06M | 420.78M | 282.68M | 171.42M | 24.79M | -149.94M | -126.89M | -23.64M |
| Cash & Equivalents | 81.22M | 78.07M | 85.03M | 447.58M | 235.60M | 101.70M | 111.87M | 85.26M | 98.89M | 158.67M | 148.69M | 178.11M | 207.78M | 94.25M | 98.56M | 95.97M | 69.81M | - | - |
| Long Term Debt | - | - | 203.59M | 670.30M | 476.71M | 347.13M | 395.96M | 335.79M | 575.14M | 875.06M | 960.17M | 985.02M | 1.24B | 1.28B | 1.58B | 1.91B | 1.89B | 1.83B | 2.09B |
| Total Liabilities | - | - | 1.01B | 1.51B | 1.42B | 1.20B | 1.22B | 1.29B | 1.38B | 1.73B | 2.00B | 2.03B | 2.37B | 2.53B | 3.16B | 3.47B | 3.51B | 3.37B | 3.74B |
| Current Liabilities | - | - | 494.68M | 542.19M | 609.84M | 561.99M | 564.19M | 678.89M | 558.21M | 587.51M | 689.67M | 734.43M | 754.51M | 840.33M | 1.15B | 1.15B | 1.18B | 1.17B | 1.20B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 223.15M | 232.60M | 268.28M | 280.88M | 327.70M | 345.93M | 418.91M | 439.80M | 460.76M | 516.33M | 565.00M | 603.45M | 724.70M | 908.83M | 859.07M | 965.87M | 968.35M | 955.77M |
| Investing Cash Flow | -48.70M | -72.58M | -77.02M | -132.29M | -97.26M | -86.02M | -94.32M | -100.75M | -231.46M | -217.34M | -138.94M | -99.08M | -100.36M | -314.11M | -139.40M | -131.69M | -119.46M | -193.87M |
| Financing Cash Flow | -178.53M | -157.44M | 167.92M | -360.47M | -366.40M | -249.89M | -348.23M | -319.96M | -163.60M | -319.53M | -388.02M | -477.37M | -743.91M | -590.55M | -716.04M | -859.59M | -855.98M | -755.17M |
| Capital Expenditure | -61.01M | -60.04M | -73.94M | -98.50M | -95.59M | -82.35M | -89.39M | -82.51M | -123.96M | -127.43M | -142.73M | -97.34M | -92.49M | -107.58M | -121.24M | -105.32M | -103.90M | -107.12M |
| Free Cash Flow | 162.14M | 172.56M | 194.34M | 182.38M | 232.12M | 263.58M | 329.52M | 357.29M | 336.80M | 388.90M | 422.28M | 506.11M | 632.21M | 801.25M | 737.83M | 860.55M | 864.45M | 848.65M |
| Share Buybacks | 229.67M | 5.99M | 240.00M | 204.58M | 278.67M | 294.98M | 414.00M | 494.97M | 499.99M | 400.00M | 475.00M | 775.00M | 775.00M | 1,000.00M | 1.10B | 900.00M | 850.00M | 800.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 50.3% | 51.4% | 52.7% | 52.8% | 53.0% | 53.9% | 54.7% | 56.4% | 57.3% | 57.8% | 57.4% | 57.9% | 58.4% | 58.4% | 58.9% | 59.2% | 60.1% | 59.4% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | 10.3% | 10.0% | 11.8% | 11.7% | 12.4% | 12.9% | 13.6% | 14.7% | 15.3% | 13.8% | 17.5% | 18.6% | 19.5% | 20.7% | 22.3% | 20.8% | 22.3% | 21.6% |
| ROE % | 40.3% | 24.3% | 30.1% | 34.5% | 35.2% | 32.7% | 47.0% | 60.8% | 88.4% | 68.7% | 86.9% | 133.3% | 213.2% | 448.6% | 3,519.1% | -526.1% | -680.2% | -3,677.4% |
| ROCE % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.76% | 1.77M | $2.30B |
| 2 | Vanguard Capital Management LLC | 6.54% | 1.32M | $1.71B |
| 3 | Capital International Investors | 5.35% | 1.08M | $1.40B |
| 4 | Vanguard Portfolio Management LLC | 4.93% | 996.08K | $1.29B |
| 5 | State Street Corporation | 4.66% | 942.53K | $1.22B |
| 6 | Alliancebernstein L.P. | 3.75% | 757.11K | $981.21M |
| 7 | T. Rowe Price Investment Management, Inc. | 3.62% | 732.05K | $948.74M |
| 8 | Bank Of New York Mellon Corporation | 3.48% | 703.48K | $911.71M |
| 9 | Geode Capital Management, LLC | 3.00% | 605.74K | $785.04M |
| 10 | Fundsmith LLP | 2.81% | 568.52K | $736.80M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MTD
Is Mettler-Toledo International (MTD) Stock Rich Or Still Reasonable? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxPVVVhMllQdUZtR0ZXcko3dHRrQ2dCdXdHQ0t0Q0RQeThvRTdiNW15SkRWUlhNLXQybHBYY0E0dHNVNEVtd2dxM0Y3eGNENnVDSXNZS3BGd19BY0ZLYl9nQlZBQTNwYlFaVy16akRzMzVTS3VOeTNwNll0MTVqWEotUV9mWVNDR0VHMHJZRF…
Sumitomo Mitsui Trust Group Inc. Reduces Stock Position in Mettler-Toledo International, Inc. $MTD - MarketBeat
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxOSHVpQzFxMFhEZE8yOTNuS0cwdlNxTUphZTFrYW1PZXdMMWUybXhqanRuYXNROFl0eGdoNDhDR2c0SkFwc3FwU1NkVjh5VVlxMURha19EQkVvZE1PVjZtV2NQeVloTHpBMFo4SUlZdUk3X0xIeWpKMTZNanJIZ1lYbHZ3TVlQUVdyamZTUG…
1 S&P 500 Stock with Competitive Advantages and 2 We Find Risky - StockStory
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOOHFWY21UaXdYYWxBNnFxR2N4eG55SjV5bl9lbmRMbi15ZXJQQTh1SVdWZDZOQVJ0eGFJVXRTc0h1b0VEYTBpMnItSHh0Vzc2TXhaZVk2TS1Vc2tRbTdKVUhrWXVhQXBzWDlmNDR1ZVZFQkNodVZNVUZWcGZPOEN2VzZCWVJRTERLY2Mtek…
Mettler-Toledo sets July 31 call for Q2 2026 results - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxOaUNwVjV1T19pTHRQUWoxYURmZURxaHdvWFVub190ak5FM3AzQW1KaVR6d0VHdUI0Y2FWcUtXZ1J6Xy1OTThBVmoyVDZQcGo1eEU2Slp3U19JM2VSWDVoLVJLNGVFbE1NNHdudzdKaDJEY1hvd2NvZTJmLXNpMkNQTGZjZDJNWDdwSlRrVj…
What Mettler-Toledo International (MTD)'s Russell 1000 Removal and Margin Strains Means For Shareholders - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQY3FyVjg3akdmbzBmcHdlU0tNZzlka2M2WGlwZUt0ODI1V1lncVBqSEd5UHQybU96ckc2QjlsRUdrcEdGUE1BVHZqclI5aE9DUm85ODJQNk9yVlZjeVNicnpVRmo0STZUaVNySFNNdmtDUUFEMmdGM1R4RF9zTm9CVnJfWXYwc0ZQdVRNaF…
Price-Driven Insight from (MTD) for Rule-Based Strategy - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxQU1JuSUFWWGJISFktZlllbmZzUW8zdGNlUWo4Y0w4VkRJamItZlVvcEx4MjZrUFRGeXhMVndfa2JLZFZWOEEzdTRyLVgwWTl4MGVnb1pISVJfcEt5RjIybVdGUE9MRjNrYk5FT2NJdVl2MV9DdTlxaXNZUFZpWXVCMVo4YkQ5QmtraHU1Tn…
MTD — Frequently Asked Questions
What is the current share price of Mettler-Toledo International Inc. (MTD)?
As of 2026-07-14 21:23 PDT, Mettler-Toledo International Inc. (MTD) trades at $1,314.83 on NYSE. Its 52-week range is $1,025.53 to $1,506.02.
What is the market capitalisation of MTD?
Mettler-Toledo International Inc. (MTD) has a market capitalisation of $26.57B on NYSE.
What is the P/E ratio of MTD?
MTD trades at a trailing price-to-earnings (P/E) ratio of 30.91. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is -545.82.
Is MTD a good stock to buy?
This page provides a data-driven analysis of Mettler-Toledo International Inc. (MTD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.